---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-355664"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2026-08-18T21:00:14+00:00"
generated_at: "2026-08-18T21:02:24.708610+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amgen terminates Crohn's disease collaboration with TScan; effective Nov 10, 2026

## Summary
- Amgen gave notice Aug 12, 2026 to terminate Research Collaboration and License Agreement; effective Nov 10, 2026.
- No early termination penalty; TScan received $30M upfront in 2023, potential milestones over $500M now unlikely.
- Collaboration used TScan's target discovery platform for Crohn's disease; Amgen had exclusive worldwide license.
- TScan expects no future milestone/royalty payments unless Amgen continues to exploit product candidates.

## SEC filing metadata
- accession: 0001193125-26-355664
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2026-08-18T21:00:14+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312526355664/0001193125-26-355664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312526355664/d143845d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-355664
- JSON: https://secwatch.observer/filing/0001193125-26-355664.json
- Plain text: https://secwatch.observer/filing/0001193125-26-355664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.